Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Refametinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 20/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 6/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 1.00 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Refametinib SCHEMBL345334 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29385439 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL345333 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29360059 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29358040 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL346872 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL10314890 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL29398471 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| SCHEMBL16127640 | 0.94 | MAP2K1 (0.89) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 | |
| Refametinib SCHEMBL3691191 | 0.94 | MAP2K1 (0.88) | MAP2K1MAP2K2CHEK1MAPK10PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3931183-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12116365-B2 | Heterocyclic compounds and uses thereof | Opna Bio SA (CH) | 2024-10-15 | — | — | US | disclosed |
| WO-2024182311-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | RYNE BIOTECHNOLOGY INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-3700574-B1 | FORMULATIONS OF A COMPOUND MODULATING KINASES | PLEXXIKON INC (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024015637-A1 | GLUTATHIONE PEROXIDASE 4 (GPX4) INHIBITORS FOR THE TREATMENT OF CANCER | Ferro Therapeutics, Inc. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4295912-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Daiichi Sankyo, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2022-11-10 | — | — | US | disclosed |
| EP-4071149-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Immuno Oncology, SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-20220184079-A1 | FORMULATIONS OF A COMPOUND MODULATING KINASES | PLEXXIKON INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220153737-A1 | SOLID FORMS OF A COMPOUND MODULATING KINASES | DAIICHI SANKYO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220081436-A1 | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES | Opna Bio SA (CH) | 2022-03-17 | — | — | US | disclosed |
| CN-114008024-A | Compounds having iron death inducing activity and methods of using the same | 费罗治疗公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | CYP11B2, CYP11B1, UGT2B7 | MAP2K1 4818/4885MAP2K2 4786/4885CHEK1 3544/4885 |
| US-20220184079-A1 | FORMULATIONS OF A COMPOUND MODULATING KINASES | PLK1, MAP3K20, MAP3K1 | MAP2K1 275/4885MAP2K2 127/4885CHEK1 41/4885 |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | MAP2K1 3021/4885MAP2K2 2695/4885CHEK1 281/4885 |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | MAP2K1 4818/4885MAP2K2 4786/4885CHEK1 3544/4885 |
| US-20220081436-A1 | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES | MAP4K2, MAP4K1, MAP3K6 | MAP2K1 236/4885MAP2K2 74/4885CHEK1 126/4885 |
| US-20220153737-A1 | SOLID FORMS OF A COMPOUND MODULATING KINASES | FLT3, KIT, ABL1 | MAP2K1 103/4885MAP2K2 57/4885CHEK1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.